



SGO Annual Meeting on Women's Cancer®

NEW ORLEANS

March 24 – 27, 2018

Oral Abstracts and Featured Posters



Society of Gynecologic Oncology

Saturday, March 24, 2018

OPENING SCIENTIFIC PLENARY SESSION I ABSTRACTS 1-6

Abstract 1

GOG 3007, a randomized phase II (RP2) trial of everolimus and letrozole (EL) or hormonal therapy (medroxyprogesterone acetate/tamoxifen, PT) in women with advanced, persistent or recurrent endometrial carcinoma (EC): A GOG Foundation study

B. Slomovitz^{1,2}, V.L. Filiaci³, R.L. Coleman⁴, J.L. Walker⁵, A.C. Fleury⁶, L.L. Holman⁷ and D.S. Miller⁸

¹University of Miami Sylvester Comprehensive Cancer Center, Miami, FL, USA, ²University of Miami Miller School of Medicine, Miami, FL, USA, ³Gynecologic Oncology Group Statistical and Data Center, Buffalo, NY, USA, ⁴The University of Texas MD Anderson Cancer Center, Houston, TX, USA, ⁵The University of Oklahoma, Oklahoma City, OK, USA, ⁶Women's Cancer Center of Nevada, Las Vegas, NV, USA, ⁷The University of Oklahoma Health Sciences Center, Oklahoma City, OK, USA, ⁸The University of Texas Southwestern Medical Center, Dallas, TX, USA

Abstract 2

Novel intrauterine polymer system delivers everolimus at biologically active levels in rats

J.A. Dottino¹, Y. Jiang¹, S. Shah², J. Celestino¹, E. Watson³, Q. Zhang¹, G. Chisholm¹, J. Burks¹, A. Mikos³, K.H. Lu¹ and M. Yates¹

¹The University of Texas MD Anderson Cancer Center, Houston, TX, USA, ²Baylor College of Medicine, Houston, TX, USA, ³Rice University, Houston, TX, USA

Abstract 3

Disparities in the allocation of research funding to gynecologic cancers demonstrated by funding to lethality scores

R. Spencer¹, L.W. Rice¹, C.Y. Ye¹ and S. Uppal²

¹University of Wisconsin School of Medicine and Public Health, Madison, WI, USA, ²University of Michigan Health Systems, Ann Arbor, MI, USA

Abstract 4

Changes in the Affordable Care Act affecting women: Fiscal 2014-2017

E.J. Pavlik¹, M. Geiger², J.C. Dillon², C. Sheffer², T.E. Pavlik², E.A. Harvey², B. Wagner², Q. Yu², L.A. Baldwin³ and M.S. Johnson³

¹University of Kentucky, Lexington, KY, USA, ²University of Kentucky College of Medicine, Lexington, KY, USA, ³University of Kentucky Medical Center, Lexington, KY, USA

Abstract 5

The Affordable Care Act reduced racial and socioeconomic disparities in access to health insurance among women diagnosed with a gynecologic malignancy

H.A. Moss, L.J. Havrilesky and J. Chino

Duke University Medical Center, Durham, NC, USA

Abstract 6

Participation in clinical trials may overcome health disparities in the treatment of advanced or recurrent epithelial ovarian cancer

K.B. Patel¹, A. Pyrzak², H. Williams², H. Coste¹, L.F. Zhang¹, R. Sadek¹, J.J. Wallbillich¹, S. Ghamande² and B.J. Rungruang¹

¹Medical College of Georgia, Augusta, GA, USA, ²Georgia Regents University, Augusta, GA, USA

**SCIENTIFIC PLENARY SESSION II: CONTEMPORARY CHALLENGES
ABSTRACTS 7-13**

10:30 a.m. – 12:00 p.m.

Abstract 7

Tackling the opioid crisis: Implementation of an ultra-restrictive opioid prescription protocol in patients undergoing major gynecologic surgery radically decreased dispensed opioid without reducing pain control

J.E. Mark¹, D. Phoenix¹, C.A. Gutierrez², K. Morrell¹, K.H. Eng¹, P.C. Mayor¹, S.N. Akers¹, S.B. Lele¹, K. Odunsi¹, O. DeLeon¹, P.J. Frederick¹ and E. Zsiros¹

¹Roswell Park Cancer Institute, Buffalo, NY, USA, ²University of Buffalo, Buffalo, NY, USA

Abstract 8

Opioid use in gynecology oncology patients after minimally invasive hysterectomy

E. Weston¹, C. Raker², D. Huang³, A.B. Parker², K.M. Robison² and C.A. Mathews²

¹Johns Hopkins School of Medicine, Baltimore, MD, USA, ²Women & Infants Hospital, Brown University, Providence, RI, USA, ³University of California, San Francisco, San Francisco, CA, USA

Abstract 9

Variation of cost and resource utilization associated with the surgical management of women with ovarian cancer

J.A. Rauh-Hain¹, A. Melamed², L.A. Meyer¹ and M.G. del Carmen³

¹The University of Texas MD Anderson Cancer Center, Houston, TX, USA, ²Massachusetts General Hospital, Boston, MA, USA, ³Massachusetts General Hospital/Harvard University, Boston, MA, USA

Abstract 10**Development of an alternative payment model (APM) for early-stage cervical cancer: Opportunities to reduce cost and improve quality**

J.D. Wright¹, L.J. Havrilesky², R.D. Alvarez³, D.E. Cohn⁴, Y. Huang¹, L.R. Boyd⁵ and E.M. Ko⁶
¹Columbia University College of Physicians and Surgeons, New York, NY, USA, ²Duke University Medical Center, Durham, NC, USA, ³University of Alabama at Birmingham, Birmingham, AL, USA, ⁴The Ohio State University, James Cancer Hospital, Columbus, OH, USA, ⁵New York University School of Medicine, New York, NY, USA, ⁶University of Pennsylvania, Philadelphia, PA, USA

Abstract 11**GOG 244, the lymphedema and gynecologic cancer (LEG) study: Incidence and risk factors in newly diagnosed patients**

J.W. Carlson¹, J. Kauderer², A. Hutson², J. Carter³, J.A. Armer⁴, S. Lockwood⁵, S. Nolte⁶, L. Wenzel⁷, J.L. Walker⁸, A.C. Fleury⁹, A.J. Bonebrake¹⁰, J.T. Soper¹¹, C.A. Mathews¹², O. Zivanovic³, W.E. Richards¹³, D.S. Alberts¹⁴ and R.R. Barakat³
¹Mercy Clinic - Women's Oncology, Springfield, MO, USA, ²Gynecologic Oncology Group Statistical and Data Center, Buffalo, NY, USA, ³Memorial Sloan Kettering Cancer Center, New York, NY, USA, ⁴University of Missouri, Columbia, MO, USA, ⁵SGNO, Fort Worth, TX, USA, ⁶Abington Memorial Hospital, Abington, PA, USA, ⁷University of California, Irvine, Irvine, CA, USA, ⁸The University of Oklahoma, Oklahoma City, OK, USA, ⁹Women's Cancer Center of Nevada, Las Vegas, NV, USA, ¹⁰Cox Health, Springfield, MO, USA, ¹¹University of North Carolina at Chapel Hill, Chapel Hill, NC, USA, ¹²Women & Infants Hospital, Brown University, Providence, RI, USA, ¹³Lewis Cancer & Research Pavilion @ St. Joseph's Candler, Savannah, GA, USA, ¹⁴The University of Arizona Cancer Center, Tucson, AZ, USA

Abstract 12**The FILM Trial: A randomized phase III multicenter study assessing near infrared fluorescence in the identification of sentinel lymph nodes (SLN)**

M. Frumovitz¹, M. Plante², P.S. Lee³, S. Sandadi Sr.⁴, J.F. Lilja⁵, P.F. Escobar⁶, L.T. Gien⁷, M.F. Munsell¹ and N.R. Abu-Rustum⁴
¹The University of Texas MD Anderson Cancer Center, Houston, TX, USA, ²Laval University, L'Hotel-Dieu de Quebec, Quebec City, QC, Canada, ³Duke University Medical Center, Durham, NC, USA, ⁴Memorial Sloan Kettering Cancer Center, New York, NY, USA, ⁵Bay Area Gynecology Oncology, San Jose, CA, USA, ⁶Instituto Gyneco-Oncologico, Caguas, PR, USA, ⁷Sunnybrook Odette Cancer Center, Toronto, ON, Canada

Abstract 13**Sentinel lymph node (SLN) isolated tumor cells (ITCs) in otherwise stage I/II endometrioid endometrial cancer: To treat or not to treat?**

F.J. Backes¹, A.S. Felix², J. Grégoire³, M. Plante⁴, S.A. Sullivan⁵, E.C. Rossi⁵, E.J. Tanner III⁶, K.I. Stewart⁷, P.T. Soliman⁷, D. Cohen², R.W. Holloway⁸, N.R. Abu-Rustum⁹ and M.M. Leitao Jr.⁹
¹The Ohio State University, James Cancer Hospital, Columbus, OH, USA, ²The Ohio State University, Columbus, OH, USA, ³L'Hotel-Dieu de Quebec, Quebec City, QC, Canada, ⁴Laval University, L'Hotel-Dieu de Quebec, Quebec City, QC, Canada, ⁵University of North Carolina at Chapel Hill, Chapel Hill, NC, USA, ⁶Johns Hopkins Hospital, Baltimore, MD, USA, ⁷The University of Texas MD Anderson Cancer Center, Houston, TX, USA, ⁸Florida Hospital Cancer Institute, Orlando, FL, USA, ⁹Memorial Sloan Kettering Cancer Center, New York, NY, USA

EDUCATION FORUM III: IMMUNOTHERAPY

ABSTRACT 14-15

3:30 p.m. – 5:00 p.m.

Abstract 14

An *in vitro* evaluation of neoantigens derived from gene fusion events in ovarian cancer patients

M.S. Ross¹, M. Tianzhou², N. Priedigkeit², L. Zhang², G. Tseng³, A.V. Lee², R.P. Edwards¹ and A. Vlad⁴

¹Magee-Womens Hospital of UPMC, Pittsburgh, PA, USA, ²University of Pittsburgh/Magee-Womens Hospital, Pittsburgh, PA, USA, ³University of Pittsburgh, Pittsburgh, PA, USA, ⁴Magee-Womens Research Institute, Pittsburgh, PA, USA

Abstract 15

Adverse events and responses in patients with recurrent ovarian cancer undergoing early-phase immune checkpoint inhibitor clinical trials

E.M. Hinchcliff, D. Hong, H. Le, G. Chisholm, R. Iyer, A. Naing and A.A. Jazaeri

The University of Texas MD Anderson Cancer Center, Houston, TX, USA

EDUCATION FORUM III: IMMUNOTHERAPY

ABSTRACT 16

3:30 p.m. – 5:00 p.m.

Abstract 16

A cost-effectiveness analysis of three PARP inhibitors for maintenance therapy in platinum-sensitive recurrent ovarian cancer

A.Y. Liu¹, J.G. Cohen¹, C. Walsh², C.H. Holschneider³ and A.K. Sinno¹

¹University of California, Los Angeles, Los Angeles, CA, USA, ²Cedars-Sinai Medical Center, Los Angeles, CA, USA, ³David Geffen School of Medicine at UCLA, Los Angeles, CA, USA

Sunday, March 25, 2018

SUNRISE SEMINAR I: POPULATION HEALTH STRATEGIES

ABSTRACT 17

6:30 a.m. – 7:30 a.m.

Abstract 17

Utilizing the patient-reported outcomes measurement information system (PROMIS) to improve referral to ancillary support services for severely symptomatic patients with gynecologic cancer

G.M. Gressel¹, S.M. Dioun¹, M. Richley¹, A.R. Van Arsdale², S. Isani³, N.S. Nevadunsky², D. Smotkin², H.O. Smith², D.Y.S. Kuo² and A.P. Novetsky²

¹Montefiore Medical Center, Bronx, NY, USA, ²Albert Einstein College of Medicine/Montefiore Medical Center, Bronx, NY, USA, ³Albert Einstein College of Medicine, New York, NY, USA

SCIENTIFIC PLENARY III: PARP-POURRI

ABSTRACTS 18-21

8:00 a.m. – 8:50 a.m.

Abstract 18

PARP 7 has a significant role in overall survival of patients with ovarian cancer

L.H. Palavalli Parsons and J.S. Lea

The University of Texas Southwestern Medical Center, Dallas, TX, USA

Abstract 19

Bevacizumab, TKI, or PARPi? A targeted approach using composite value-based endpoints and biomarkers to individualize care for platinum-sensitive recurrent ovarian cancer (PSROC)

J.R. Foote¹, A. Alvarez-Secord¹, M.I. Liang², J.A. Ehrisman¹, D.E. Cohn³, E. Jewell⁴ and L.J. Havrilesky¹

¹Duke University Medical Center, Durham, NC, USA, ²David Geffen School of Medicine at UCLA, Los Angeles, CA, USA, ³The Ohio State University, James Cancer Hospital, Columbus, OH, USA, ⁴Memorial Sloan Kettering Cancer Center, New York, NY, USA

Abstract 20

Safety and dose modification for patients with low body weight receiving niraparib in the ENGOT-OV16/NOVA phase III trial

R. Lord¹, M.R. Mirza², L. Woelber³, A. Lesoin⁴, M.J. Pineda⁵, U. Peen⁶, S.J. Hazard⁷ and U.A. Matulonis⁸

¹National Cancer Research Institute (NCRI) and Clatterbridge Cancer Center, Wirral, United Kingdom, ²The Nordic Society of Gynecological Oncology (NSGO) and Rigshospitalet-Copenhagen University Hospital, Copenhagen, Denmark, ³Arbeitsgemeinschaft Gynäkologische Onkologie (AGO) and University Medical Center Hamburg - Eppendorf, Hamburg, Germany, ⁴Groupe d'Investigateurs Nationaux pour l'Etude des Cancers Ovariens (GINECO) and Centre Oscar Lambret Department de Cancérologie Sénologique, Lille, France, ⁵Ironwood Cancer and Research Center, Mesa, AZ, USA, ⁶NSGO and Herlev Hospital, Herlev, Denmark, ⁷Tesaro, Inc., Waltham, MA, USA, ⁸Dana-Farber Cancer Institute, Boston, MA, USA

Abstract 21

Are FDA-approved PARPi cost-effective as maintenance treatment of platinum-sensitive recurrent ovarian cancer?

J.A. Dottino¹, H.A. Moss², K.H. Lu¹, A.A. Secord³ and L.J. Havrilesky²

¹The University of Texas MD Anderson Cancer Center, Houston, TX, USA, ²Duke University Medical Center, Durham, NC, USA, ³Duke Cancer Institute, Durham, NC, USA

SCIENTIFIC PLENARY IV: CURRENT TRIALS, EMERGING TARGETS

ABSTRACTS 22-26

1:45 p.m. – 2:30 p.m.

Abstract 22

Randomized phase II trial of carboplatin-paclitaxel compared to carboplatin-paclitaxel-trastuzumab in advanced or recurrent uterine serous carcinomas that overexpress Her2/neu (NCT01367002)

A.D. Santin¹ and A.N. Fader²

¹Yale University School of Medicine, New Haven, CT, USA, ²Johns Hopkins School of Medicine, Baltimore, MD, USA

Abstract 23**Predictive biomarkers of endometrial cancer response: Results from NRG Oncology/ Gynecologic Oncology Group study 86P**

D.A. Levine¹, D.S. Dizon², J.W. Carlson³, V.L. Filiaci⁴, M.A. Powell⁵, A.A. Secord⁶, K.S. Tewari⁷, D.P. Bender⁸, D.M. O'Malley⁹, A.R. Stuckey¹⁰, K.N. Moore¹¹, S.B. Dewdney¹², J. Gao¹³, F. Dao¹, R.A. Soslow¹³, H.A. Lankes⁴ and C.A. Aghajanian¹⁴

¹NYU Langone Health, New York, NY, USA, ²Massachusetts General Hospital Cancer Center, Boston, MA, USA, ³Mercy Clinic - Women's Oncology, Springfield, MO, USA, ⁴Gynecologic Oncology Group Statistical and Data Center, Buffalo, NY, USA, ⁵Washington University School of Medicine in St. Louis, St. Louis, MO, USA, ⁶Duke Cancer Institute, Durham, NC, USA, ⁷University of California Irvine Medical Center, Orange, CA, USA, ⁸University of Iowa Hospitals and Clinics, Iowa City, IA, USA, ⁹The Ohio State University, James Cancer Hospital, Columbus, OH, USA, ¹⁰Women & Infants Hospital, Brown University, Providence, RI, USA, ¹¹The University of Oklahoma Health Sciences Center, Oklahoma City, OK, USA, ¹²Rush University Medical Center, Chicago, IL, USA, ¹³Memorial Sloan Kettering Cancer Center, New York, NY, USA, ¹⁴Weill Cornell Medical College, New York, NY, USA

Abstract 24**IAP antagonism enhances anti-tumor activity of docetaxel or panobinostat in ovarian cancer cell lines**

K.P. Zelig¹, F. Ning², L. Hernandez³, T. Smyth⁴, G. Ward⁴ and C.M. Annunziata³

¹Walter Reed National Military Medical Center, Bethesda, MD, USA, ²National Institutes of Health, Bethesda, MD, USA, ³National Cancer Institute, Bethesda, MD, USA, ⁴Astex Pharmaceuticals, Cambridge, United Kingdom

Abstract 25**Development of a high-affinity anti-galectin-3 antibody targeting interactions between MUC16/ CA-125 and galectin-3 to inhibit oncogenic properties in serous ovarian cancer**

M. Stasencko, T.D. Rao, F. Weis-Garcia and D. Spriggs

Memorial Sloan Kettering Cancer Center, New York, NY, USA

Abstract 26**Targeting the TIE2 pathway with a novel small molecule vascular endothelial protein tyrosine phosphatase (VE-PTP) inhibitor in high-grade serous ovarian cancer**

L.P. Cobb¹, A. Rickard², J. Herbert², G. Hanna², G. Palmer², S. Siamakpour-Reihani², Z. Huang², K. Peters³, C. Kontos², A. Berchuck⁴ and A.A. Secord⁵

¹Duke University School of Medicine, Durham, NC, USA, ²Duke University, Durham, NC, USA, ³Aerpio Therapeutics, Cincinnati, OH, USA, ⁴Duke University Medical Center, Durham, NC, USA, ⁵Duke Cancer Institute, Durham, NC, USA

EDUCATION FORUM V: PALLIATIVE CARE**ABSTRACT 27**

3:30 p.m. – 5:00 p.m.

Abstract 27**Trends in place of death among gynecologic cancer patients in the United States**

K. Hicks-Courant¹, A. Melamed² and J.A.A. Rauh-Hain²

¹Tufts Medical Center, Boston, MA, USA, ²Massachusetts General Hospital, Boston, MA, USA

Monday, March 26, 2018

SUNRISE SEMINAR V: HEALTH CARE ECONOMICS

ABSTRACT 28

6:30 a.m. – 7:30 a.m.

Abstract 28

Indicated presurgical testing is a priority to achieve high-quality, cost-effective oncologic health care delivery

G.J. Gardner, H. Weiss, A. Klotz, S. Ogden, D. Boccamazzo, J. Hagerty-Paglia, N.R. Abu-Rustum, K. Sepkowitz, G. Fischer and J. Drebin

Memorial Sloan Kettering Cancer Center, New York, NY, USA

FOCUSED PLENARY I: PRECLINICAL AND TRANSLATIONAL MEDICINE

ABSTRACTS 29-32

9:15 a.m. – 10:15 a.m.

Abstract 29

Simvastatin has anti-tumorigenic effects in endometrial cancer via reversal of obesity-driven upregulation of lipid biosynthesis

L. West¹, L.H. Clark¹, S.R. Pierce¹, Y. Yin¹, Z. Fang¹, D. Lee², C. Zhou¹ and V.L. Bae-Jump¹

¹*University of North Carolina at Chapel Hill, Chapel Hill, NC, USA*, ²*Omic Insight, LCC, Durham, NC, USA*

Abstract 30

Overcoming platinum resistance in ovarian cancer by targeting pregnancy-associated plasma protein-a

D. Torres, X. Hou, L.K. Bale, E.P. Heinzen, M.J. Maurer, Q. Zhang, C.A. Conover and S.J. Weroha
Mayo Clinic, Rochester, MN, USA

Abstract 31

Expression of dopamine receptor D2 in endometrial tumors and the impact of DRD2 blockade on cancer proliferation

S.R. Pierce¹, M. Asher¹, Z. Fang¹, L. West¹, Y. Yin¹, V. Prabhu², C. Xu¹, C. Zhou¹ and V.L. Bae-Jump¹

¹*University of North Carolina at Chapel Hill, Chapel Hill, NC, USA*, ²*Oncocentics, Philadelphia, PA, USA*

Abstract 32

Stromal cell expression of the receptor tyrosine kinase DDR2 promotes ovarian cancer metastasis

M. Greenwade, W.R. Grither, A.R. Hagemann, C.K. McCourt, D.G. Mutch, M.A. Powell, P.H. Thaker and K.C. Fuh

Washington University School of Medicine in St. Louis, St. Louis, MO, USA

FOCUSED PLENARY II: REDUCING COST AND PAIN

ABSTRACTS 33-37

9:15 a.m. – 10:15 a.m.

- Abstract 33** **Can the ASCO alternative payment model achieve cost savings in ovarian cancer care?**
H.A. Moss¹, M. Dinan², M.V. Georgieva², L.H. Hendrix² and L.J. Havrilesky¹
¹Duke University Medical Center, Durham, NC, USA, ²Duke Cancer Institute, Durham, NC, USA
- Abstract 34** **Evaluation of financial toxicity in women with gynecologic malignancies: A cross-sectional study**
E.M. Webster¹, S. Chatterjee², L. Gabor¹, R.M. Vattakalam¹, J.Y. Hou¹, A.I. Tergas¹ and J.D. Wright³
¹NYP/Columbia University Medical Center, New York, NY, USA, ²NYPH, Columbia University Medical Center and Weill Cornell Medical College, New York, NY, USA, ³Columbia University College of Physicians and Surgeons, New York, NY, USA
- Abstract 35** **Use of lay navigation in gynecologic oncology patients: A model to reduce costs**
R.P. Rocconi¹, P. Sharma², A. Azuero², J.M. Scalici¹, J. Young Pierce¹, N.L. Jones¹, K.S. Bevis², E.E. Partridge², E. Kvale², G.B. Rocque² and M. Pisu²
¹Mitchell Cancer Institute, University of South Alabama, Mobile, AL, USA, ²University of Alabama at Birmingham, Birmingham, AL, USA
- Abstract 36** **A comparison of liposomal bupivacaine to bupivacaine HCl in transversus abdominis planus block for abdominal gynecologic surgery: A randomized controlled trial**
H. Ching¹, R.F. Atkins¹, E.R. Burton², M.I. Edelson², J.I. Sorosky² and M.S. Shahin²
¹Abington Memorial Hospital, Abington, PA, USA, ²Hanjani Institute for Gynecologic Oncology, Abington Memorial Hospital, Abington, PA, USA
- Abstract 37** **Impact of enhanced recovery after surgery (ERAS) protocol on postoperative pain control in chronic narcotic users**
H.J. Smith, T.K.L. Boitano, T. Rushton, M.C. Johnston, C.A. Leath III and J.M. Straughn Jr.
University of Alabama at Birmingham, Birmingham, AL, USA

FOCUSED PLENARY III: NEW INSIGHTS INTO RARE TUMORS

ABSTRACTS 38-42

9:15 a.m. – 10:15 a.m.

- Abstract 38** **KMT2D/MLL2 loss of function is a novel driver of disease recurrence in adult-type granulosa cell tumors of the ovary**
R.T. Hillman, J. Celestino, K.H. Lu, D.M. Gershenson, R. Broaddus and P.A. Futreal
The University of Texas MD Anderson Cancer Center, Houston, TX, USA
- Abstract 39** **Integrated genomic analyses distinguish leiomyosarcomas arising at distinct anatomic origins**
M.L. Anderson¹ and A.J. Lazar²
¹Baylor College of Medicine, Houston, TX, USA, ²The University of Texas MD Anderson Cancer Center, Houston, TX, USA

- Abstract 40** **Single-course methotrexate and single-course combined methotrexate–dactinomycin: A phase III randomized controlled clinical trial in treatment of low-risk gestational trophoblastic neoplasm**
- L. Chen¹, R. Yin², L. Xi³, J. Jiang⁴, X. Li⁵, P. Qu⁶, B. Kong⁴, D. Ma⁷, X. Xie¹ and W. Lv¹
¹Women's Hospital, School of Medicine, Zhejiang University, Zhejiang, China, ²West China Second University Hospital, Sichuan, China, ³Tongji Hospital of Tongji Medical College, Huazhong University of Science and Technology, Wuhan, China, ⁴Qilu Hospital of Shandong University, Jinan, China, ⁵Shengjing Hospital of China Medical University, Shengyang, China, ⁶Tianjin Central Hospital of Gynecology Obstetrics, Nankai University, Tianjin, China, ⁷Tongji Hospital of Tongji Medical College, Wuhan, China
- Abstract 41** **The impact of uterine re-curettage on the number of chemotherapy courses in treatment of post molar gestational trophoblastic neoplasia: A randomized controlled study**
- R. Hemida¹, B.E. Deek¹, M. Arafa¹, E. Toson¹, E.L. Vos², C.W. Burger² and H.C.V. Doorn²
¹Mansoura University, Mansoura, Egypt, ²Erasmus University Medical Centre, Rotterdam, Netherlands
- Abstract 42** **Molecular profiling of ovarian germ cell tumors**
- M. Stasenko¹, A. Zehir¹, A. Snyder¹, D. Reales¹, D. DeLair¹, R.A. Soslow¹, N.R. Abu-Rustum¹, C.A. Aghajanian², D. Feldman¹ and D.B. Solit¹
¹Memorial Sloan Kettering Cancer Center, New York, NY, USA, ²Weill Cornell Medical College, New York, NY, USA
- SCIENTIFIC PLENARY V: FARR NEZHAT SURGICAL INNOVATION SESSION**
SURGICAL DECISION MAKING IN ADVANCED OVARIAN CANCER
ABSTRACT 43
11:15 a.m. – 12:30 p.m.
- Abstract 43** **Moving beyond “complete surgical resection” and “optimal”: Is low-volume residual disease another option?**
- B.L. Manning-Geist^{1,2}, K. Hicks-Courant³, A.A. Gockley⁴, R.M. Clark⁴, M.G. del Carmen⁵, J.O. Schorge², N.S. Horowitz⁶, R.S. Berkowitz⁶, M.G. Muto⁷ and M.J. Worley Jr.⁸
¹Brigham and Women's Hospital/Harvard Medical School, Boston, MA, USA, ²Massachusetts General Hospital, Boston, MA, USA, ³Tufts Medical Center, Boston, MA, USA, ⁴Harvard Medical School, Boston, MA, USA, ⁵Massachusetts General Hospital/Harvard University, Boston, MA, USA, ⁶Brigham and Women's Hospital, Boston, MA, USA, ⁷Dana-Farber Cancer Institute, Boston, MA, USA, ⁸Brigham and Women's Hospital/Harvard University, Boston, MA, USA
- EDUCATION FORUM X: WELLNESS**
ABSTRACTS 44-45
4:30 p.m. – 6:00 p.m.
- Abstract 44** **Career demands of gynecologic oncology have a substantial impact on family planning**
- M. Song¹, A. Kapoor¹, R. Isaksson Vogel², M.A. Geller² and D.G.K. Teoh²
¹University of Minnesota Cancer Center, Minneapolis, MN, USA, ²University of Minnesota, Minneapolis, MN, USA
- Abstract 45** **The career effects of parenting on female and male gynecologic oncologists**
- L.B. Beffa¹, A.R. Stuckey¹, E.K. Hill², A.K. Brown³, M.E. Gordinier⁴, C. Raker², M. Clark⁵ and K.M. Robison¹
¹Women & Infants Hospital, Brown University, Providence, RI, USA, ²University of Iowa, Iowa City, IA, USA, ³Hartford Hospital, Hartford, CT, USA, ⁴Norton Healthcare, Louisville, KY, USA, ⁵University of Massachusetts Medical Center, Worcester, MA, USA

Tuesday, March 27, 2018

SCIENTIFIC PLENARY VI: IMMUNO-ONCOLOGY

ABSTRACTS 46-50

7:30 a.m. – 8:30 a.m.

Abstract 46

Pembrolizumab in advanced recurrent endometrial cancer: A cost-effectiveness analysis

D.A. Barrington, S.E. Dilley, H.J. Smith and J.M. Straughn Jr.
University of Alabama at Birmingham, Birmingham, AL, USA

Abstract 47

Predictors of early treatment discontinuation in ovarian cancer patients on checkpoint blockade immunotherapy

J. Boland¹, M. Martin¹, N. Zecca¹, A. Iasonos¹, Q. Zhou¹, C.A. Aghajanian^{1,2}, P. Sabbatini^{1,2}, K.A. Cadoo^{1,2} and D. Zamarin^{1,2}
¹*Memorial Sloan Kettering Cancer Center, New York, NY, USA*, ²*Weill Cornell Medical College, New York, NY, USA*

Abstract 48

Phase II study of pembrolizumab (pembro) combined with pegylated liposomal doxorubicin (PLD) for recurrent platinum-resistant ovarian, fallopian tube or peritoneal cancer

U.A. Matulonis¹, W. Barry¹, R.T. Penson², P.A. Konstantinopoulos¹, W. Luo¹, M.A. Hoffman³, N.S. Horowitz⁴, S. Farooq¹, D.S. Dizon⁵, E. Stover¹, A.A. Wright^{1,6}, S.M. Campos¹, C. Krasner⁷ and J.F. Liu¹
¹*Dana-Farber Cancer Institute, Boston, MA, USA*, ²*Massachusetts General Hospital/Harvard University, Boston, MA, USA*, ³*Long Island Jewish Medical Center, New Hyde Park, NY, USA*, ⁴*Brigham and Women's Hospital, Boston, MA, USA*, ⁵*Lifespan Cancer Institute, Rhode Island Hospital, Warren Alpert Medical School of Brown University, Providence, RI, USA*, ⁶*Harvard Medical School, Boston, MA, USA*, ⁷*Massachusetts General Hospital, Boston, MA, USA*

Abstract 49

Phase II, two-stage study of avelumab in patients with microsatellite stable (MSS), microsatellite instable (MSI) and polymerase epsilon (POLE) mutated recurrent or persistent endometrial cancer

P.A. Konstantinopoulos¹, J.F. Liu¹, W. Barry¹, C. Krasner², M.K. Buss³, M.J. Birrer^{4,5}, S. Farooq¹, S.M. Campos¹, E. Stover¹, S. Schumer¹, A.A. Wright⁶, D.S. Dizon⁷, W. Luo¹, R.T. Penson⁴, S.A. Cannistra³, G.F. Fleming⁸ and U.A. Matulonis¹
¹*Dana-Farber Cancer Institute, Boston, MA, USA*, ²*Massachusetts General Hospital, Boston, MA, USA*, ³*Beth Israel Deaconess Medical Center, Boston, MA, USA*, ⁴*Massachusetts General Hospital/Harvard University, Boston, MA, USA*, ⁵*University of Alabama at Birmingham, Birmingham, AL, USA*, ⁶*Harvard Medical School, Boston, MA, USA*, ⁷*Lifespan Cancer Institute, Rhode Island Hospital, Warren Alpert Medical School of Brown University, Providence, RI, USA*, ⁸*University of Chicago Medical Center, Chicago, IL, USA*

Abstract 50

Gene set enrichment clustering and the tumor microenvironment in primary high-grade serous ovarian cancer (HGSOC)

P. Cybulska¹, A. Jimenez-Sanchez², K. LaVigne¹, T. Walther¹, H.A. Vargas¹, O. Zivanovic¹, B. Weigelt¹, E. Sala¹, M. Miller² and A. Snyder³
¹*Memorial Sloan Kettering Cancer Center, New York, NY, USA*, ²*University of Cambridge, Cambridge, United Kingdom*, ³*Adaptive Biotechnologies, Seattle, WA, USA*

SCIENTIFIC PLENARY VII: IMPROVING PATIENT EXPERIENCE AND OUTCOMES

ABSTRACTS 51-56

8:40 a.m. – 10:00 a.m.

- Abstract 51** **GOG 244, The lymphedema and gynecologic cancer (LEG) study: The association between the gynecologic cancer lymphedema questionnaire (GCLQ) and lower extremity lymphedema**
- J. Carter¹, H. Huang², J.A. Armer³, J.W. Carlson⁴, S. Lockwood⁵, S. Nolte⁶, B.R. Stewart³, L. Wenzel⁷, J. Kauderer², A. Hutson², J.L. Walker⁸, A.C. Fleury⁹, J.T. Soper¹⁰, C.A. Mathews¹¹, O. Zivanovic¹, W.E. Richards¹², D.S. Alberts¹³ and R.R. Barakat¹
- ¹Memorial Sloan Kettering Cancer Center, New York, NY, USA, ²Gynecologic Oncology Group Statistical and Data Center, Buffalo, NY, USA, ³University of Missouri, Columbia, MO, USA, ⁴Mercy Clinic - Women's Oncology, Springfield, MO, USA, ⁵SGNO, Fort Worth, TX, USA, ⁶Abington Memorial Hospital, Abington, PA, USA, ⁷University of California, Irvine, Irvine, CA, USA, ⁸The University of Oklahoma, Oklahoma City, OK, USA, ⁹Women's Cancer Center of Nevada, Las Vegas, NV, USA, ¹⁰University of North Carolina at Chapel Hill, Chapel Hill, NC, USA, ¹¹Women & Infants Hospital, Brown University, Providence, RI, USA, ¹²Lewis Cancer & Research Pavilion @ St. Joseph's Candler, Savannah, GA, USA, ¹³The University of Arizona Cancer Center, Tucson, AZ, USA
- Abstract 52** **Patient-reported symptom burden and functional recovery before and after enhanced recovery after surgery (ERAS) implementation: A comparison between open and minimally invasive surgery**
- L.A. Meyer¹, Q. Shi¹, J.D. Lasala¹, A.M. Nick², M.D. Iniesta¹, A.M. Siverand¹, C. Corzo¹, X.S. Wang¹, K.H. Lu¹ and P.T. Ramirez¹
- ¹The University of Texas MD Anderson Cancer Center, Houston, TX, USA, ²St. Thomas Medical Partners, University of Tennessee Health Sciences Center, Nashville, TN, USA
- Abstract 53** **Gestational trophoblastic disease electronic consults: What do patients and physicians want to know?**
- R. Nitecki¹, N.S. Horowitz², K.M. Elias², D.P. Goldstein³ and R.S. Berkowitz²
- ¹Brigham and Women's Hospital/Harvard Medical School, Boston, MA, USA, ²Brigham and Women's Hospital, Boston, MA, USA, ³Brigham and Women's Hospital/Harvard University, Boston, MA, USA
- Abstract 54** **It's like "magic": The mobile application for genetic information on cancer**
- M.A. Geller, R. Isaksson Vogel, H.Y. Lee, K. Niendorf, H.W. Lee and S.V. Petzel
- University of Minnesota, Minneapolis, MN, USA
- Abstract 55** **Rethinking cervical cancer screening guidelines in an aging U.S. population**
- S.E. Dilley, J.A. O'Donnell, H.J. Smith, S. Bae and W. Huh
- University of Alabama at Birmingham, Birmingham, AL, USA
- Abstract 56** **Patient-reported outcomes after surgery for endometrial carcinoma: Prevalence of lower extremity lymphedema after sentinel lymph node mapping (SLNM) compared to lymphadenectomy**
- M.M. Leitao Jr.¹, N.R. Gómez-Hidalgo², A. Iasonos¹, Q. Zhou¹, M. Mezzancello¹, K. Chang¹, J. Ward¹, R.R. Barakat¹, D.S. Chi¹, K. Long Roche¹, Y. Sonoda¹, C.L. Brown¹, J.J. Mueller¹, G.J. Gardner¹, E. Jewell¹, V. Broach¹, O. Zivanovic¹, S.C. Dowdy³, A. Mariani³ and N.R. Abu-Rustum¹
- ¹Memorial Sloan Kettering Cancer Center, New York, NY, USA, ²NYP/Columbia University Medical Center, New York, NY, USA, ³Mayo Clinic, Rochester, MN, USA

SCIENTIFIC PLENARY VIII: LAST BUT NOT LEAST...

ABSTRACTS 57-60

10:00 a.m. – 11:00 a.m.

Abstract 57

A novel site-specific proteomic screening test for ovarian cancer in a large prospective multi-institutional clinical study

R.P. Rocconi, J.M. Scalici, L. Schambeau, L. Pannell and M.A. Finan
Mitchell Cancer Institute, University of South Alabama, Mobile, AL, USA

Abstract 58

Evidence for synthetic lethality between bevacizumab and chemotherapy in advanced, p53 null endometrial cancers

A.R. Mallen¹, V.L. Filiaci², D.A. Levine³, K. Thiel⁴, C.A. Aghajanian⁵, X. Meng⁶, E. Devor⁶, K.N. Moore⁷, M.A. Powell⁸, A.A. Secord⁹, K.S. Tewari¹⁰, D.P. Bender⁶, A.R. Stuckey¹¹, J.M. Fowler¹², S.B. Dewdney¹³ and K.K. Leslie⁶

¹Moffitt Cancer Center-University of South Florida, Tampa, FL, USA, ²Gynecologic Oncology Group Statistical and Data Center, Buffalo, NY, USA, ³New York University School of Medicine, New York, NY, USA, ⁴University of Iowa Carver College of Medicine, Iowa City, IA, USA, ⁵Weill Cornell Medical College, New York, NY, USA, ⁶University of Iowa Hospitals and Clinics, Iowa City, IA, USA, ⁷The University of Oklahoma Health Sciences Center, Oklahoma City, OK, USA, ⁸Washington University School of Medicine in St. Louis, St. Louis, MO, USA, ⁹Duke Cancer Institute, Durham, NC, USA, ¹⁰University of California Irvine Medical Center, Orange, CA, USA, ¹¹Women & Infants Hospital, Brown University, Providence, RI, USA, ¹²The Ohio State University, James Cancer Hospital, Columbus, OH, USA, ¹³Rush University Medical Center, Chicago, IL, USA

Abstract 59

Randomized trial of adjuvant chemotherapy versus concurrent chemoradiotherapy in early-stage cervical cancer after radical surgery: A Chinese Gynecologic Oncology Group study (CSEM-002)

D. Weng¹, H. Wang¹, C. Zhu², B. Cui³, C. Wang¹, K. Li¹, Q. Gao¹, X. Cheng², X. Yang³, J. Jiang³, Y. Zhang³, B. Kong³, X. Xie² and D. Ma¹

¹Tongji Hospital of Tongji Medical College, Huazhong University of Science and Technology, Wuhan, China, ²Women's Hospital, School of Medicine, Zhejiang University, Zhejiang, China, ³Qilu Hospital, Shandong University, Jinan, China

Abstract 60

Come back in six months, or never? Defining surveillance and survivorship in gynecologic malignancies with an evidence-based approach

R.L. Dood, Y. Zhao, S. Armbruster, C.J. LaFargue, O.D. Lara, G.Z. Dal Molin, A.K. Sood and K.A. Baggerly
The University of Texas MD Anderson Cancer Center, Houston, TX, USA

FEATURED POSTERS

- Abstract 61** **Benign surgery performed by gynecologic oncologists: Is selection bias altering our ability to measure surgical quality?**
- E.L. Barber¹, A.L. Alexander¹, S. Shahabi² and E.C. Rossi³
¹Northwestern University Feinberg School of Medicine, Chicago, IL, USA, ²Western CT Health Network/Danbury Hospital, Danbury, CT, USA, ³University of North Carolina at Chapel Hill, Chapel Hill, NC, USA
- Abstract 62** **Racial disparities in hereditary gynecologic cancer risk assessment: What and why?**
- D.A. Barrington, S. Batra, G. McGwin, T.B. Turner, A. Brown, M.B. Farmer, J.M. Straughn Jr. and C.A. Leath III
University of Alabama at Birmingham, Birmingham, AL, USA
- Abstract 63** **The utility of preoperative PET/CT in the detection of extrauterine disease in high-risk endometrial cancer: A prospective study**
- K.I. Stewart¹, B. Chasen¹, W.D. Erwin¹, N.D. Fleming¹, S.N. Westin¹, M. Frumovitz¹, P.T. Ramirez¹, S.M. Dioun², K.H. Lu¹, F. Wong¹ and P.T. Soliman¹
¹The University of Texas MD Anderson Cancer Center, Houston, TX, USA, ²Montefiore Medical Center, Bronx, NY, USA
- Abstract 64** **A comprehensive genomic analysis of neuroendocrine carcinoma of gynecologic and breast tumors**
- P.C. Mayor¹, L. Gay², K. Fan³, P.J. Frederick¹, R.N. Eskander⁴, J. Sun², J.S. Ross⁵, R. Kurzrock⁶, S.N. Akers¹, S.B. Lele¹, K. Odunsi¹, E. Zsiros¹ and J.A. Elvin²
¹Roswell Park Cancer Institute, Buffalo, NY, USA, ²Foundation Medicine, Inc., Cambridge, MA, USA, ³University of Buffalo, Buffalo, NY, USA, ⁴UCSD Rebecca and John Moores Cancer Center, La Jolla, CA, USA, ⁵Albany Medical College, Albany, NY, USA, ⁶University of California San Diego, La Jolla, CA, USA
- Abstract 65** **Development and validation of a risk calculator for adverse perioperative outcomes for women with ovarian cancer**
- S. Cham, A.I. Tergas, J.Y. Hou, C. St. Clair, C. V. Ananth, D.L. Hershman and J.D. Wright
NYP/Columbia University Medical Center, New York, NY, USA
- Abstract 66** **Nedaplatin and paclitaxel compared with carboplatin and paclitaxel for patients with platinum-sensitive recurrent ovarian cancer**
- L. Ge¹, N. Li² and L.Y. Wu²
¹National Cancer Center/Cancer Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing, China, ²Cancer Hospital, Chinese Academy of Medical Sciences, Beijing, China

- Abstract 67** **A subgroup of cases with a high immunogenic profile in homologous recombination-proficient high-grade serous ovarian carcinoma: Possible candidates for checkpoint blockade therapy**
- K. Hasegawa¹, H. Matsushita², K. Oda², S. Yamamoto³, K. Asada², A. Yabuno¹, A. Nishijima², T. Karasaki², Y. Ikeda¹, K. Fujiwara¹, H. Aburatani³ and K. Kakimi²
¹Saitama Medical University International Medical Center, Hidaka, Japan, ²The University of Tokyo Hospital, Tokyo, Japan, ³Research Center for Advanced Science and Technology, The University of Tokyo, Tokyo, Japan
- Abstract 68** **Cytoreductive surgery and hyperthermic intraperitoneal chemotherapy as initial treatment of ovarian, fallopian tube, and primary peritoneal cancer: Preliminary results of a phase II randomized clinical trial**
- T.P. Diaz-Montes, F. El-Sharkawy, V. Gushchin, H.S. Ryu, M. Sittig and A. Sardi
Mercy Medical Center, Baltimore, MD, USA
- Abstract 69** **Utilization of preoperative PET-CT and pelvic MRI reduces multimodality therapy in the care of women with early-stage cervical carcinoma**
- E.J. Diver¹, E.M. Hinchcliff¹, A.A. Gockley², A. Melamed¹, L. Contrino³, S. Feldman³ and W.B. Growdon²
¹Massachusetts General Hospital, Boston, MA, USA, ²Harvard Medical School, Boston, MA, USA, ³Brigham and Women's Hospital, Boston, MA, USA
- Abstract 70** **Identification of ovarian cancer patients for immunotherapy by concurrent assessment of tumor mutation burden (TMB), microsatellite instability (MSI) status, and targetable genomic alterations (GA)**
- J. Feinberg¹, J.A. Elvin², S. Bellone¹ and A.D. Santin¹
¹Yale University School of Medicine, New Haven, CT, USA, ²Foundation Medicine, Inc., Cambridge, MA, USA
- Abstract 71** **Evaluation of circulating tumor DNA in patients with endometrial cancer harboring somatic PIK3CA or KRAS mutations: A potential high-risk factor for recurrence**
- D. Shintani¹, T. Hihara², A. Ogasawara³, A. Yabuno³, K. Fujiwara¹, K. Tai² and K. Hasegawa¹
¹Research Center for Genomic Medicine, Saitama Medical University, Hidaka, Japan, ²Tsukuba Research Laboratories, Eisai Co., Ltd, Tsukuba, Japan, ³Saitama Medical University International Medical Center, Hidaka, Japan
- Abstract 72** **Tackling the opioid crisis: Reduced postoperative oral and intravenous opioid use after implementation of an enhanced recovery after surgery (ERAS) program in gynecologic oncology patients**
- H.J. Gray¹, C. Rind¹, E.S. Wu¹, B.A. Goff¹, H.K. Tamimi¹, K. Pennington² and R.R. Urban¹
¹University of Washington Medical Center, Seattle, WA, USA, ²University of Washington School of Medicine, Seattle, WA, USA

Abstract 73**GOG 8035: Nuclear *BRCA1* loss may identify a poor prognostic subgroup of women with locally advanced cervical cancer treated with cisplatin-based chemoradiation: An NRG Oncology study**

T.C. Longoria¹, M. Sill², B.J. Monk³, J. Fruehauf⁴, S.Y. Liao⁵, R. Emerson⁶, J.H. Kim¹, R.S. Mannel⁷, Y.C. Lee⁸, C.A. Mathews⁹, L.M. Randall¹, K.M. Darcy¹⁰, M.J. Birrer¹¹ and K.S. Tewari¹

¹University of California Irvine Medical Center, Orange, CA, USA, ²Gynecologic Oncology Group Statistical and Data Center, Buffalo, NY, USA, ³University of Arizona Cancer Center, Phoenix, AZ, USA, ⁴University of California, Irvine, Orange, CA, USA, ⁵St. Joseph's Hospital and Medical Center, Urbana, IL, USA, ⁶Indiana University School of Medicine, Indianapolis, IN, USA, ⁷The University of Oklahoma Health Sciences Center, Oklahoma City, OK, USA, ⁸SUNY Downstate, Brooklyn, NY, USA, ⁹Women & Infants Hospital, Brown University, Providence, RI, USA, ¹⁰Gynecologic Cancer Center of Excellence, John P. Murtha Cancer Center, Walter Reed National Military Medical Center, Uniformed Services University of the Health Sciences, Annandale, VA, USA, ¹¹Massachusetts General Hospital/Harvard University, Boston, MA, USA

Abstract 74**Initial safety and activity findings from a phase IB escalation study of mirvetuximab soravtansine, a folate receptor alpha (FR α -targeting antibody-drug conjugate (ADC), with pembrolizumab in platinum-resistant epithelial ovarian cancer (EOC) patients**

U.A. Matulonis¹, K.N. Moore², L.P. Martin³, I.B. Vergote⁴, C.M. Castro⁵, L. Gilbert⁶, A. Berkenblit⁷, M.J. Birrer⁸ and D.M. O'Malley⁹

¹Dana-Farber Cancer Institute, Boston, MA, USA, ²The University of Oklahoma Health Sciences Center, Oklahoma City, OK, USA, ³Fox Chase Cancer Center, Philadelphia, PA, USA, ⁴University Hospital Leuven, Leuven, Belgium, ⁵Massachusetts General Hospital, Boston, MA, USA, ⁶McGill University Health Centre, Montreal, QC, Canada, ⁷ImmunoGen, Inc., Waltham, MA, USA, ⁸Massachusetts General Hospital/Harvard University, Boston, MA, USA, ⁹The Ohio State University, James Cancer Hospital, Columbus, OH, USA

Abstract 75**Concordance of germline multigene panel testing with prior microsatellite instability and immunohistochemistry analyses in endometrial cancer patients**

K. Jasperson¹, C.R. Espenschied¹, H. Hampel², P. Reineke¹, T. Pesaran¹, V. Speare¹, J. Profato¹ and I.M. Frayling³

¹Ambry Genetics, Aliso Viejo, CA, USA, ²The Ohio State University Comprehensive Cancer Center, Columbus, OH, USA, ³Cardiff University, Cardiff, United Kingdom

Abstract 76**Sentinel lymph node mapping (SLNM) in endometrioid endometrial cancer: Does it work in the real world?**

O. Valieva¹, D.M. Greer², J.J.F. Kram², E. Schmit¹, E.L. Dickson¹ and S.A. Kamelle²

¹Aurora Health Care, Gurnee, IL, USA, ²Aurora Health Care, Milwaukee, WI, USA

Abstract 77**Germline *BRCA* mutation rate in Southern California Latina women**

L.J. Hong¹, R. Gonzalez², S. Abu-Tabikh², L. Cristiano², J. Unternaehrer-Hamm¹ and Y.J.M. Ioffe¹

¹Loma Linda University School of Medicine, Loma Linda, CA, USA, ²Loma Linda University Medical Center, Loma Linda, CA, USA

Abstract 78**Phase I trial of Vigil[®] personalized engineered autologous tumor cells (EATC) in ovarian cancer**

R.P. Rocconi¹, J.M. Scalici¹, M. Barve², L. Manning³, G. Wallraven³, N. Senzer³ and J. Nemunaitis³

¹Mitchell Cancer Institute, University of South Alabama, Mobile, AL, USA, ²Texas Oncology, P.A., Dallas, TX, USA, ³Gradalis, Inc., Dallas, TX, USA

- Abstract 78** **A prospective, randomized control trial evaluating the impact of backfill versus spontaneous voiding trial on discharge time for gynecologic oncology patients undergoing laparoscopic hysterectomy**
- M.R. Davis¹, K.E. Barletta², A.T. Ford³, R. Nitecki², K.M. Elias⁴, M.J. Worley Jr.¹, R.S. Berkowitz⁴, M.G. Muto⁵, N.S. Horowitz⁴ and C.M. Feltmate⁴
¹Brigham and Women's Hospital/Harvard University, Boston, MA, USA, ²Brigham and Women's Hospital/Harvard Medical School, Boston, MA, USA, ³Emory University, Atlanta, GA, USA, ⁴Brigham and Women's Hospital, Boston, MA, USA, ⁵Dana-Farber Cancer Institute, Boston, MA, USA
- Abstract 79** **Adoptive dendritic cell transfer following platinum-based chemotherapy extends overall host survival in a preclinical model of metastatic ovarian cancer**
- A. Buskwofie¹, E. Teran-Cabanillas², T. Sandoval Medina² and J.R. Cubillos-Ruiz²
¹NYPH, Columbia University Medical Center and Weill Cornell Medical College, New York, NY, USA, ²Weill Cornell Medical College, New York, NY, USA
- Abstract 80** **Zoptec: Phase III randomized controlled study comparing zoptarelin with doxorubicin as second line therapy for locally advanced, recurrent, or metastatic endometrial cancer (NCT01767155)**
- D.S. Miller¹, A. Oaknin², R.M. Wenham³, A.M. Oza⁴, I.B. Vergote⁵, A. Westermann⁶, D.L. Tait⁷ and H. Gabra⁸
¹The University of Texas Southwestern Medical Center, Dallas, TX, USA, ²GEICO (Grupo Espanol de Investigacion en Cancer de Ovario), Barcelona, Spain, ³H. Lee Moffitt Cancer Center & Research Institute, Tampa, FL, USA, ⁴Princess Margaret Cancer Centre, University Health Network, Toronto, ON, Canada, ⁵University Hospital Leuven, Leuven, Belgium, ⁶Academic Medical Centre, Amsterdam, Netherlands, ⁷Levine Cancer Institute, Carolinas Medical Center, Charlotte, NC, USA, ⁸Imperial College Healthcare NHS Trust, London, United Kingdom
- Abstract 81** **Vaginal brachytherapy is associated with improved overall survival in stage IB endometrioid endometrial carcinoma: A propensity matched, National Cancer Data Base study**
- M.M. AlHilli¹, S. Amarnath¹ and S.C. Dowdy²
¹The Cleveland Clinic Foundation, Cleveland, OH, USA, ²Mayo Clinic, Rochester, MN, USA
- Abstract 82** **Favorable tumor immunophenotype is associated with homologous recombination deficiency in ovarian carcinoma**
- C.B. Morse¹, M.N. Toukatly¹, M.I. Harrell², K.J. Agnew³, S.S. Bernards³, B.M. Norquist², K. Pennington³, M.R. Kilgore¹, R.L. Garcia¹ and E.M. Swisher¹
¹University of Washington Medical Center, Seattle, WA, USA, ²University of Washington, Seattle, WA, USA, ³University of Washington School of Medicine, Seattle, WA, USA
- Abstract 83** **Comparative efficacy and tolerability of the PARP inhibitors, olaparib 300 mg tablets BID, niraparib 300 mg capsules QD and rucaparib 600 mg tablets BID as maintenance treatment in BRCA-mutated (BRCAm) platinum-sensitive relapsed ovarian**
- A. Sackeyfio¹, F. Nussey², M. Friedlander³ and E. Pujade-Lauraine⁴
¹AstraZeneca, Cambridge, United Kingdom, ²Western General Hospital, Edinburgh, United Kingdom, ³Prince of Wales Hospital, Randwick, Australia, ⁴Hôpital Hotel Dieu, Paris, France

- Abstract 84** **Immune checkpoint expression, microsatellite instability, and mutational burden: Identifying immune biomarker phenotypes in uterine cancer**
- N.L. Jones¹, J. Xiu², T. Herzog³ and I. Winer⁴
¹Mitchell Cancer Institute, University of South Alabama, Mobile, AL, USA, ²Caris Life Sciences, Irving, TX, USA, ³UC Health Barrett Cancer Center, Cincinnati, OH, USA, ⁴Wayne State University, Detroit, MI, USA
- Abstract 85** **Mutational burden, tumor immune checkpoint expression, and microsatellite instability in gynecologic malignancies: Implications for immune therapy**
- I. Winer¹, N.L. Jones², J. Xiu³, A. Ellerbrock³, J. Brown⁴ and T. Herzog⁵
¹Wayne State University, Detroit, MI, USA, ²Mitchell Cancer Institute, University of South Alabama, Mobile, AL, USA, ³Caris Life Sciences, Irving, TX, USA, ⁴Levine Cancer Institute, Carolinas Medical Center, Charlotte, NC, USA, ⁵UC Health Barrett Cancer Center, Cincinnati, OH, USA
- Abstract 86** **Improving the efficacy of PARP inhibition with a novel ATR inhibitor, ATRN119, in ovarian high-grade serous cancers**
- E. George¹, H. Kim², L.R. Butler³, M.A. Morgan², O. Gilad³, E.J. Brown¹ and F. Simpkins²
¹Hospital of the University of Pennsylvania, Philadelphia, PA, USA, ²University of Pennsylvania, Philadelphia, PA, USA, ³Atrin Pharmaceuticals, Doylestown, PA, USA
- Abstract 87** **System-wide implementation of a perioperative practice-changing bundle to lower surgical site infections in gynecologic oncology: Outcome effect and impact of variations in compliance**
- A.S. O'Shea, B.F. Lees, R. Harrison, R. Spencer, L.M. Barroilhet, E.M. Hartenbach, L.W. Rice, S.L. Rose and A.N. AL-Niaimi
University of Wisconsin School of Medicine and Public Health, Madison, WI, USA
- Abstract 88** **CA-125 is a useful predictor of disease status in uterine carcinosarcoma**
- M.S. Ross¹, C.K. Chandler¹, E. Elishaev¹, N. Siripong², J. Berger¹, J.L. Kelley III¹ and S.E. Taylor¹
¹Magee-Womens Hospital of UPMC, Pittsburgh, PA, USA, ²University of Pittsburgh/Magee-Womens Hospital, Pittsburgh, PA, USA